Compare ADMA Biologics Inc (ADMA) vs Teucrium Corn Fund (CORN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Teucrium Corn Fund — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Teucrium Corn Fund trades at $17.4. The key difference: Teucrium Corn Fund is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | CORN | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $20.38 | $19.12 |
52-Week Low | $7.60 | $16.46 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
CORN stock trades at $17.45, up 3.5% today, with a bullish technical signal from moving averages and oscillators. Key support is at $17 and resistance at $18. Recent news includes a licensing partnership with Hormel Foods for CORN NUTS® brands (GlobeNewsWire, 2026-05-07).
The outlook is cautiously optimistic given technical momentum, but fundamental data is unavailable. Risks include reliance on brand licensing and broader market volatility. Investors should monitor upcoming earnings for financial health indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Teucrium Corn Fund
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →
